The Relevance of Selenium Status in Rheumatoid Arthritis.
Francisco Javier Turrubiates-HernándezYolanda Fabiola Márquez-SandovalGuillermo González-EstevezZyanya Reyes-CastilloJosé Francisco Munoz-VallePublished in: Nutrients (2020)
Rheumatoid arthritis (RA) is an autoimmune and inflammatory disease that can cause joint damage. Among the environmental risk factors, diet plays an important role because it can aggravate or attenuate inflammation. Selenium (Se) is considered an essential trace element since it is a structural component of antioxidant enzymes; however, its concentration can be affected by diet, drugs and genetic polymorphisms. Studies have reported that RA patients have a deficient diet in some food groups that is associated with parameters of disease activity. Furthermore, it has been shown that there is an alteration in serum Se levels in this population. Although some clinical trials have been conducted in the past to analyze the effect of Se supplementation in RA, no significant results were obtained. Contrastingly, experimental studies that have evaluated the effect of novel Se nanoparticles in RA-induced models have shown promising results on the restoration of antioxidant enzyme levels. In particular, glutathione peroxidase (GPx) is an important selenoprotein that could have a modulating effect on inflammation in RA. Considering that RA patients present an inflammatory and oxidative state, the aim of this review is to give an overview of the current knowledge about the relevance of Se status in RA.
Keyphrases
- rheumatoid arthritis
- disease activity
- oxidative stress
- ankylosing spondylitis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- end stage renal disease
- interstitial lung disease
- ejection fraction
- risk factors
- newly diagnosed
- physical activity
- chronic kidney disease
- weight loss
- prognostic factors
- multiple sclerosis
- patient reported outcomes
- diabetic rats
- endothelial cells
- hydrogen peroxide
- drug induced
- human health
- heavy metals
- idiopathic pulmonary fibrosis
- phase iii